A Study to Predict Lung Cancer Using Noninvasive Biomarkers

Overview

About this study

The purpose of this study is to improve the efficiency of the diagnostic evaluation of patients with indeterminate pulmonary nodules.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

Arm 1 - Screening

  • Age 55-77 years old.
  • Current and former smokers with 30 pack-years or more(and quit less than 15 years ago)

 Arm 2 - Incidental

  • Age > 45 years old.
  • Current and former smokers with 10 pack-years or more (and quit less than 15 years ago).

Exclusion Criteria:

  • History or previous diagnosis of primary lung cancer, metastatic lung cancer, or any other non-lung cancer within 5 years (not including non-melanoma skin cancer).
  • Any receipt of cytotoxic agents within the past 6 months.
  • Symptoms of lung cancer (unexplained weight loss 10 lbs or more in 3 months, recent hemoptysis).
  • Diagnosis of pure ground glass opacities for the target lesion on chest CT within the last 12 months (i.e., mixed features on the target lesion and pure ground glass opacity on non-target lesions are acceptable as mentioned above).

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Tobias Peikert, M.D.

Closed for enrollment

Contact information:

Jodi Mahon

(507) 293-0694

Mahon.Jodi@mayo.edu

More information

Publications

Publications are currently not available
.
CLS-20490902

Mayo Clinic Footer